

**SECTION I**  
**AMENDMENTS TO THE SPECIFICATION**

**Please insert the following replacement paragraph in the specification at page 6, lines 16-18:**

In a particularly preferred embodiment of the conjugate according to the invention, the peptide-nucleic acid (PNA) comprises the following sequence: ATTGTTAGATTTCAT (SEQ ID NO: 1) (orientation: N-terminus/sequence/C-terminus).

**Please insert the following replacement paragraph in the specification at page 7, lines 9-12:**

The sequence (SEQ ID NO: 3) of the anti-gene PNA directed against an ampicillin resistance is shown in the figure below. The underlined region of the beta-lactamase-encoding pDNA sequence of pBR322 corresponds to the target region for the PNA conjugate.

**Please insert the following replacement paragraph in the specification at page 7, lines 16-17:**

The amino acid sequences (SEQ ID NOs: 4-31) of the 28 individual holins are shown in the one-letter code. Fig. 3(1) shows SEQ ID NO: 24-31, Fig.3(2) shows SEQ ID NOs: 4-11, Fig. 3(3) shows SEQ ID NOs: 11-19, Fig. 3(4) shows SEQ ID NOs: 20-22, and Fig. 3(5) shows SEQ ID NO: 23.

**Please insert the following replacement paragraph in the specification at page 10, lines 4-8:**

The sequence of the PNA directed against an ampicillin resistance was as follows: H<sub>2</sub>N-ATTGTTAGATTTCAT-COOH (SEQ ID NO: 1). This is a sequence which can hybridize with the region of position 86 to position 100 of the pDNA of pBR322 (GeneBank accession number J01749). The sequence of the PNA used against the kanamycin resistance was H<sub>2</sub>N-TCTTGTTCAATCAT-COOH (SEQ ID NO: 2).

**THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK**